Tempol-nebivolol therapy potentiates hypotensive effect increasing NO bioavailability and signaling pathway

Abstract

Nebivolol is a third generation beta blocker with endothelial nitric oxide synthase (eNOS) agonist properties. Considering the role of reactive oxygen species (ROS) in the uncoupling of eNOS, we hypothesized that the preadministration of an antioxidant as tempol, could improve the hypotensive response of nebivolol in normotensive animals increasing the nitric oxide (NO) bioavailability by a reduction of superoxide (O 2 .-) basal level production in the vascular tissue. Male Sprague Dawley rats were given tap water to drink (control group) or tempol (an antioxidant scavenger of superoxide) for 1 week. After 1 week, Nebivolol, at a dose of 3 mg/kg was injected intravenously to the control group or tempol treated group. Mean arterial pressure, heart rate and blood pressure variability were evaluated in the control, tempol, nebivolol and tempol nebivolol groups, as well as, the effect of different inhibitor as N W -nitro-l-arginine methyl ester (L-NAME, a Nitric oxide synthase blocker) or glybenclamide, a K ATP channel inhibitor. Also, the expression of α,β soluble guanylate cyclase (sGC), phospho-eNOS, and phosphovasodilator-stimulated phosphoprotein (P-VASP) were evaluated by Western Blot and cyclic guanosine monophosphate (cGMP) levels by an enzyme-linked immunosorbent assay (ELISA) commercial kit assay.We showed that preteatment with tempol in normotensive rats produces a hypotensive response after nebivolol administration through an increase in the NO bioavailability and sGC, improving the NO/ cGMP/ protein kinase G (PKG) pathway compared to the nebivolol group.We demonstrated that tempol preadministration beneficiates the response of a third generation beta blocker with eNOS stimulation properties, decreasing the basal uncoupling of eNOS and improving NO bioavailability. Our results clearly open a possible new strategy therapeutic for treating hypertension.Free Radic Res Downloaded from informahealthcare.com by Loyola University on 10/05/13For personal use only. For personal use only. J U S T A C C E P T E D J U S T A C C E P T E D AbstractNebivolol is a third generation beta blocker with endothelial nitric oxide synthase (eNOS) agonist properties. Considering the role of reactive oxygen species (ROS) in the uncoupling of eNOS, we hypothesized that the preadministration of an antioxidant as tempol, could improve the hypotensive response of nebivolol in normotensive animals increasing the nitric oxide (NO) bioavailability by a reduction of superoxide (O 2 .-) basal level production in the vascular tissue.Male Sprague Dawley rats were given tap water to drink (control group) or tempol (an antioxidant scavenger of superoxide) for 1 week. After 1 week, Nebivolol, at a dose of 3 mg/kg was injected intravenously to the control group or tempol treated group. Mean arterial pressure, heart rate and blood pressure variability were evaluated in the control, tempol, nebivolol and tempol nebivolol groups, as well as, the effect of different inhibitor as N W -nitro-l-arginine methyl ester (L-NAME, a Nitric oxide...

Effect of Entresto on Clinical Symptoms, Ventricular Remodeling, Rehabilitation, and Hospitalization Rate in Patients with Both Acute Myocardial Infarction and Acute Heart Failure

“…Therefore, we also tested VR-related metrics in both groups and found that the obs group showed significantly better improvements in these metrics. According to reports [ 16 , 17 ], Entresto has a dual-target regulation mechanism, and its mechanism of action is the same as that of enalapril. It can participate in natriuretic expansion, blood pressure reduction, myocardial remodeling reversal and cardiac function by inhibiting enkephalase and upregulating natriuretic peptide and bradykinin.…”

Butterfly Pea Flower (Clitoria ternatea Linn.) Extract Ameliorates Cardiovascular Dysfunction and Oxidative Stress in Nitric Oxide-Deficient Hypertensive Rats

“…•− and plasma malondialdehyde (MDA) levels, as well as a reduction in NO metabolites (NOx), have been described in L-NAME-induced hypertensive rats [5,6,17,18]. Subsequently, eNOS uncoupling has been demonstrated to be a major source of superoxide generations in L-NAME hypertensive rats [19,20]. Low levels of endogenous antioxidant enzymes, such as superoxide dismutase, catalase, and glutathione, have been noted in NO-deficient hypertensive rats [21].…”

Adrenergic Blockade by Nebivolol to Suppress Oral Squamous Cell Carcinoma Growth via Endoplasmic Reticulum Stress and Mitochondria Dysfunction

“…In this study, we confirmed that nebivolol could upregulate the expression of iNOS in OSCC cells and contribute to the activation of the NO signal pathway. Nebivolol was reported to beneficiate the response of the NO signal pathway to relieve hypertension ( Varagic et al, 2010 ; Bertera et al, 2014 ). NO is synthesized by NO synthase (NOS) and as a multifunctional signaling molecule.…”